This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Nucleic Acid Amplification Tests (NAATs) for the Diagnosis of Pharyngeal and Rectal Chlamydia and Gonorrhea Infections

Sponsored by Centers for Disease Control and Prevention

About this trial

Last updated 14 years ago

Study ID

CDC-NCHSTP-3881

Status

Completed

Type

Interventional

Phase

N/A

Placebo

No

Accepting

16+ Years
All Sexes

Trial Timing

Ended 16 years ago

What is this trial about?

Investigators at the University of Alabama in Birmingham in collaboration with investigators from the Centers for Disease Control in Atlanta are evaluating the performance of three commercial nucleic acid amplification tests for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in pharyngeal and rectal swab specimens. Cultures for C. trachomatis and N. gonorrhoeae are performed as additional reference tests. Study subjects are men and women attending sexually transmitted disease (STD) and HIV care clinics in Birmingham, Alabama, who report sexual behaviors that place them at risk for pharyngeal or rectal sexually transmitted infections.

What are the participation requirements?

Inclusion Criteria

* Age greater than 15 years.

* If male, history of fellatio, cunnilingus, or receptive anal sex within the last two months.

* If female, presenting for treatment of N. gonorrhoeae and/or C. trachomatis or contact to N. gonorrhoeae, C. trachomatis, or nongonococcal urethritis.

* If female, history of fellatio or history of anal sex within the last two months.

Exclusion Criteria

* Declines to participate.

* History of receipt of antimicrobial agents active against N. gonorrhoeae or C. trachomatis in the preceding 30 days.